We are 2,6-Dimethylphenol CAS:576-26-1 manufacturer and supplier in China, Pls send inquiry of to firstname.lastname@example.org of visit www.nbinno.com our official website should you have any interests
CAS No: 576-26-1
Product Name: 2,6-Dimethylphenol
Density: 1.0±0.1 g/cm3
Boiling Point: 201.1±0.0 °C at 760 mmHg
Melting Point: 43-45 °C(lit.)
Molecular Formula: C8H10O
Molecular Weight: 122.164
Flash Point: 78.3±0.0 °C
Exact Mass: 122.073166
Vapour Pressure: 0.2±0.4 mmHg at 25°C
Index of Refraction: 1.540
Stability: Stable. Very flammable. Incompatible with oxidizing agents, acid chlorides, acid anhydrides, steel, copper, copper alloys, bases, acid chlorides.
Water Solubility: 10 g/L (20 ºC)
Appearance: White or light yellow crystalline powder
Melting Point: 45~48℃
Applicationd in organic synthesis and antisepsis, medicine, solvents and antioxidants.
It is used in the production of polyphenylene ether resin, photographic agents, pesticides, polyesters and polyether resins. It is also the raw material of antiarrhythmic drugs for slow heart rhythm.
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Related News: In 2016, the export volume of China’s specialty drug substances reached US $ 3.53 billion, accounting for 13.8% of the total drug substances.N4-Isobutylquinoline-3,4-diamine CAS:99010-09-0 In 2016, the export volume of China’s specialty drug substances reached US $ 3.53 billion, accounting for 13.8% of the total drug substances.γ-Butyrolactone CAS:96-48-0 Exceeding impurities in the drug substance may cause the product and its preparation to be recalled. The company receives an FDA warning letter or a CEP certificate suspension, which in turn will cause customer compensation, product recall costs, and asset impairment losses to affect the company’s performance.Piridoxal-5-fosfato CAS:54-47-7 The outlook for a cure is clouded with theoretical uncertainties and high-profile failures. Pharmaceutical giants including Johnson & Johnson, Merck and Pfizer have ditched their projects on unsatisfactory data.Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application.